-
Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Juan Carlos Vallejo Llamas, Koo Wilson, Zalmaï Hakimi, Barbara Czech, Sam Williamson, +4 more
1citations -
Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
Hans Jürgen Salwender, Michael Hundemer, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, +27 more
1citations -
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Hartmut Goldschmidt, Uta Bertsch, Ema Požek, Axel Benner, Roland R. Fenk, Britta Besemer, +26 more
1citations -
Thrombosis and Encapsulated Bacterial Infection Rates in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Pegcetacoplan: Nearly 3 Years of Post-Marketing Experience2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Gloria Frances Gerber, Richard Kelly, Hisakazu Nishimori, Regina Horneff, Peter Hillmen, Uchendu Orizu Uchendu, +2 more
1citations -
A multinational study to explore patient preferences for chronic myeloid leukaemia treatments2025 Blood conference-abstract Economics, Econometrics and Finance Economic and Environmental Valuation Open access
Jan Geißler, Šarūnas Narbutas, Hannah Hussain, Priscila Radu, David John Mott, Tim H. Brümmendorf, +8 more
1citations -
Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Nadja Jaekel, Susann Schulze, Christina Zahn, Andreas Wienke, Michael Richter, Steffen Koschmieder, +5 more
1citations -
Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
Josu de la Fuente, Jacques‐Emmanuel Galimard, Arnaud Dalissier, Mohsen Al Zahrani, Ali Debsan Alahmari, Ashrafsadat Mousavi, +14 more
1citations -
Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT
Josu de la Fuente, Dirk‐Jan Eikema, Paul V. Bosman, Robert Wynn, Miguel Ángel Díaz, Peter John Shaw, +24 more
1citations -
Modifiable Risk Factors Are Associated with Reduced Bone Mineral Density and Fractures in a National Cohort of 2,003 Dutch Childhood Cancer Survivors
Demi T.C. de Winter, Jenneke E. van Atteveld, Vincent G. Pluimakers, Marta F. Fiocco, Rutger A. J. Nievelstein, Monique G. G. Hobbelink, +19 more
1citations -
Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
Laurent Garderet, Luuk A. Gras, Linda Köster, Anita D’Souza, Noel Estrada‐Merly, Parameswaran Hari, +38 more
1citations -
Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
Peter A. von dem Borne, Tjeerd J.F. Snijders, Daniëlle van Lammeren, Janneke Tijmensen, Erwin V. Planken, Henriëtte Levenga, +9 more
1citations -
Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT
Firoozeh Sahebi, Dirk‐Jan Eikema, Linda Köster, Nicolaus Martin Kröger, Ellen Meijer, Goda Choi, +19 more
1citations